Helicon Therapeutics Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Helicon Therapeutics General Information
Description
Developer of therapies for memory related diseases. The company specializes in the design and development of drugs to enhance the formation of long term memory.
Contact Information
Website
www.helicontherapeutics.comCorporate Office
- 7473 Lusk Boulevard
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 7473 Lusk Boulevard
- Suite 100
- San Diego, CA 92121
- United States
Helicon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 01-Jan-2012 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series G) | 13-Apr-2011 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series F) | 24-Jun-2009 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series E) | 01-Nov-2006 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 15-Jul-2005 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C2) | 12-May-2003 | Completed | Startup | |||
| 3. Later Stage VC (Series C) | 03-Dec-2001 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 10-Jan-2001 | $6M | $9.8M | Completed | Startup | |
| 1. Early Stage VC (Series A) | $3.75M | $3.75M | Completed | Startup |
Helicon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C2 | ||||||||
| Series C | ||||||||
| Series B | 5,382,224 | $0.001000 | 10% | $1.1 | $1.1 | 1x | $1.1 | 3.95% |
| Series A | 2,309,808 | $0.001000 | 10% | $1.1 | $1.1 | 1x | $1.1 | 1.7% |
Helicon Therapeutics Patents
Helicon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2711031-A1 | Neurite outgrowth as an assay for memory enhancing compounds | Inactive | 27-Dec-2007 | ||
| AU-2008345015-A1 | Neurite outgrowth as an assay for memory enhancing compounds | Inactive | 27-Dec-2007 | ||
| EP-2235239-A1 | Neurite outgrowth as an assay for memory enhancing compounds | Inactive | 27-Dec-2007 | ||
| EP-2235239-A4 | Neurite outgrowth as an assay for memory enhancing compounds | Inactive | 27-Dec-2007 | ||
| JP-2015110666-A | Therapeutic isoxazole compounds | Inactive | 27-Aug-2007 | C07D491/044 |
Helicon Therapeutics FAQs
-
When was Helicon Therapeutics founded?
Helicon Therapeutics was founded in 1997.
-
Where is Helicon Therapeutics headquartered?
Helicon Therapeutics is headquartered in San Diego, CA.
-
What industry is Helicon Therapeutics in?
Helicon Therapeutics’s primary industry is Drug Discovery.
-
Is Helicon Therapeutics a private or public company?
Helicon Therapeutics is a Private company.
-
What is Helicon Therapeutics’s current revenue?
The current revenue for Helicon Therapeutics is .
-
How much funding has Helicon Therapeutics raised over time?
Helicon Therapeutics has raised $121M.
-
When was Helicon Therapeutics acquired?
Helicon Therapeutics was acquired on 01-Jan-2012.
-
Who acquired Helicon Therapeutics?
Helicon Therapeutics was acquired by Dart NeuroScience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
